Ability Biotherapeutics Moves to Inspire Bio Innovations in Montreal, Pioneering the New Generation of Targeted Antibodies
MONTREAL — Ability Biotherapeutics, a Quebec-based leader in antibody therapeutics, is proud to announce its new location at Inspire Bio Innovations. The company will occupy the 6th floor of Phase 2 in the transformative redevelopment of the former Montreal Chest Institute, marking a significant step in its growth within Montreal's thriving life sciences ecosystem.
Article content
Article content
The project's first phase is scheduled for completion this summer, with the second phase, including Ability's new space, expected to wrap up by the end of 2026. Ability Biotherapeutics is pioneering a new generation of targeted antibody therapies for cancer and autoimmune diseases, powered by its proprietary generative AI-based AbiLeap™ platform. Ability is advancing multiple drug discovery programs, with three lead programs now entering optimization and development as it prepares for preclinical studies. Taking advantage of Inspire Bio Innovations' dynamic environment, Ability plans to complete preclinical studies to demonstrate the effectiveness of its therapeutic products and to begin large-scale production in preparation for the first human clinical trials. These steps are expected to enable the company to triple its number of employees by 2028.
Article content
Since its unveiling less than two years ago, the Inspire project has sparked genuine enthusiasm within the life sciences ecosystem. Initially hosting the headquarters of Cellcarta, it has since brought together various Montreal universities and the Montreal Clinical Research Institute (IRCM). The project gained international recognition by being awarded the title of Future Office Project of the Year at the prestigious World Architecture Festival (WAF). This life sciences hub is already attracting a community of forward-thinking researchers and entrepreneurs focused on innovation, and continues to welcome companies from around the world seeking to thrive in its dynamic environment.
Article content
Located in the heart of downtown Montreal, Inspire Bio Innovations offers an ideal location with easy access via public and active transportation and proximity to major highways. This life sciences innovation hub is strategically located near a vibrant community of research centres and top-tier researchers, including MILA, CR-CHUM, CR-CUSUM, IRCM, and IRIC. This proximity will significantly enhance interactions and knowledge sharing. Additionally, being close to major hospitals like CHUM and MUHC will streamline the execution of local clinical studies. These factors make Inspire Bio Innovations highly attractive for retaining current talent and recruiting global experts.
Article content
'We are excited to pursue our activities within Inspire Bio Innovations, a cutting-edge hub that fosters exchanges and interactions with top-tier researchers and innovative entrepreneurs. The collaborative environment created by Jadco is ideal for advancing the development of therapies with the potential to transform the treatment of patients with cancer or autoimmune diseases, both in Québec and globally.'—Patrick Tremblay, Ph.D., Chief Operating Officer at Ability Biotherapeutics.
Article content
'We firmly believe that Inspire Bio Innovations is the ideal hub for nurturing the next generation of researchers and innovators who will propel the entire life sciences ecosystem forward. Montreal possesses all the attributes necessary to strengthen its role as one of the most dynamic and promising international centres in this field. This new space, dedicated to innovation and precision medicine, will unite talented teams whose work will continue this tradition while facilitating the commercialization of discoveries.'—Normand Rivard, Managing Partner, Life Sciences and Innovation, Jadco Group.
Article content
'Ability Biotherapeutics' addition to the Inspire Bio Innovations scientific hub once again demonstrates the excellence of this innovation centre dedicated to scientific research. This new partnership strengthens the project's leading role in biotechnology. We are delighted to see this promising collaboration take shape in Plateau-Mont-Royal.'—Luc Rabouin, Leader of Projet Montréal.
Article content
About Ability Biotherapeutics
Ability Biotherapeutics is the next-generation biotherapeutics company developing logic-gated antibodies with exceptional contextual selectivity and stability, driving safer, more effective immunotherapies for cancer and autoimmune diseases. Its proprietary platform, AbiLeap™, uses generative AI powered by one of the largest and exclusively held, therapeutically relevant human antibody databases, providing distinct insights for sequence space exploration. Combining AI with in vitro display and screening technologies, AbiLeap™ generates fully human antibodies that are conditionally activated and multi-specific, directing therapeutic targeting to specific cells and disease sites. This approach enables solutions for indications with high unmet clinical needs by reducing toxicity and significantly broadening the therapeutic window, maximizing treatment benefits. Ability's experienced team is committed to revolutionizing targeted therapeutics to transform patient outcomes and redefine industry standards. www.ability.bio
Article content
Article content
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Cision Canada
2 hours ago
- Cision Canada
BST Global Receives Frost & Sullivan's 2025 Global AEC Project Management Company of the Year Award for Excellence in Market Leadership and Digital Transformation
Market-leading innovation, AI-enabled project intelligence ™, and a customer-first approach are transforming the AEC project management industry. SAN ANTONIO, Aug. 4, 2025 /CNW/ -- Frost & Sullivan is pleased to announce that BST Global has received the 2025 Global Company of the Year Award in the architecture, engineering, and consulting (AEC) project management industry for its outstanding achievements in innovation, performance, and customer impact. This top honor recognizes BST Global's leadership in transforming the AEC project management landscape through cutting-edge technology and a customer-centric business model. Frost & Sullivan evaluates companies through a rigorous benchmarking process across two core dimensions: strategy effectiveness and strategy execution. BST Global excelled in both, demonstrating its ability to align strategic initiatives with emerging AEC market demands—such as increasing project complexity and skilled workforce shortages—while executing them with scale and precision. Guided by a long-term strategy focused on digital transformation and customer satisfaction, BST Global has reshaped how AEC firms manage project performance. With AEC companies facing industry-wide challenges—from rising material costs and labor shortages to increasingly remote operations and outdated legacy systems—BST Global delivers intuitive, AI-powered solutions that reduce complexity, improve decision making, and increase productivity. Innovation remains at the core of BST Global's approach. The company's AI-enabled project intelligence platform includes BST Insights, which leverages more than 35 discrete digital signals to provide real-time visibility into project health using net labor multiplier (NLM) as a predictive KPI. "BST Insights predicts outcomes with a 95% or higher accuracy rate for qualified projects, enabling project managers and project directors to make meaningful changes to how their projects are resourced in real time, for example, identifying roles that can be staffed more cost effectively to better align with the economic footprint of the project," said Lynda Stadtmueller, Associate Partner, Information & Communications Technology, Frost & Sullivan. BST Global also introduced BST Connect ™, a cloud-based iPaaS launched in 2024. It integrates seamlessly with systems such as Oracle CX and Microsoft Dynamics, enabling enterprise-wide connectivity. "Earning this honor from Frost & Sullivan reflects the transformative work our team and our clients are doing together to redefine project management in the AEC industry," said Eileen M. Canady, Chief Marketing Officer at BST Global. "We're proud to lead with innovation—infusing AI and real‑time insights into project delivery—while never losing sight of what matters most: enabling our clients to thrive in an increasingly complex and competitive environment." BST Global's consumer-grade mobile applications and Waze-inspired user interface reduce training time and accelerate user adoption. Whether clients are migrating from on-premises solutions or embracing BST Global's latest cloud-native platforms, the company supports them with tailored implementation, data migration, and ongoing reporting services to ensure a smooth, effective transition. Frost & Sullivan commends BST Global for setting the standard in market responsiveness, ecosystem collaboration, and customer experience. The company's launch of the AI + Data Consortium in October 2024 further demonstrates its commitment to advancing the AEC industry through collective benchmarking and standard setting. Each year, Frost & Sullivan presents the Company of the Year Award to a company that demonstrates outstanding strategy development and implementation, resulting in measurable improvements in market share, customer satisfaction, and competitive positioning. The honor recognizes forward-thinking organizations that are reshaping their industries through innovation and growth excellence. Frost & Sullivan Best Practices Awards Frost & Sullivan's Best Practices Awards honor companies across regional and global markets that exhibit exceptional achievement and consistent excellence in areas such as leadership, technological innovation, customer experience, and strategic product development. Each recognition is the result of a rigorous analytical process in which Frost & Sullivan industry experts benchmark performance through comprehensive interviews, deep-dive analysis, and extensive secondary research. The goal is to identify true best-in-class organizations that are driving transformative growth and setting new industry standards. Contact us: Start the discussion. Contact: E: About BST Global BST Global designs, develops and deploys the AEC industry's first suite of AI-powered project intelligence ™ solutions. Beyond our flagship ERP offering, we provide work management, predictive insights and resource management solutions to complement a firm's existing ERP. More than 120,000 architects, engineers and consultants in 65 countries across six continents rely on BST Global's solutions each day to successfully manage their projects, resources, finances and client relationships. With unrivaled industry knowledge, BST Global serves as a trusted partner to its loyal clients and remains at the forefront of innovation. For more information, visit
Cision Canada
3 hours ago
- Cision Canada
Pulsecare Medical Announces NMPA Approval of NxPFA™, the World's First Nanosecond PFA System, Ushering in the PFA 3.0 Era
SHENZHEN, China, Aug. 4, 2025 /CNW/ -- Pulsecare Medical, a pioneer in cardiovascular intervention technologies, announced that its innovative NxPFA™ nanosecond pulsed field ablation (ns-PFA) systemhas received marketing approval from China's National Medical Products Administration (NMPA). As the world's first third-generation ns-PFA system utilizing high-voltage nanosecond pulses for pulmonary vein isolation (PVI) in atrial fibrillation (AF) treatment, this breakthrough marks the dawn of the PFA 3.0 era and represents the innovative capabilities of Pulsecare Medical in cardiovascular multimodal therapy. The World's First Commercially Approved Nanosecond PFA PFA has revolutionized AF treatment through its tissue selectivity, safety, and procedural efficiency. Yet, early-generation systems using microsecond pulses face key challenges—excessive muscle stimulation, reliance on general anesthesia, and risks like hemolysis and gas embolism—that limit broad adoption. As the world's first and only commercially available nanosecond PFA system, NxPFA™ represents the "Next of PFA" generation. It combines the MaviPulse™ high repetition frequency ns-PFA console with the InteShot™ basket-shaped catheter to deliver irreversible electroporation of cardiomyocytes via high-voltage nanosecond pulses, effectively overcoming key limitations of microsecond PFA (μs-PFA) technologies: Significantly reduces neuromuscular stimulation, enabling procedures under conscious sedation, improving patient comfort and lowering anesthesia risks; Combines nanosecond pulses with a basket-shaped catheter to ensure optimal electrode-tissue contact and high success rates, while shortening procedural time; Substantially lowers intravascular gas formation, lowering the risk of stroke or systemic embolism; Minimizes erythrocytic damage and post-procedural bilirubin elevation, reducing potential kidney injury. NxPFA™ Demonstrates Outstanding Efficacy and Safety The NxPFA ™ system has been clinically validated through the SCENA-AF multicenter registration trial, which enrolled 166 patients with paroxysmal atrial fibrillation. The data has been acknowledged by NMPA and will soon be published in an academic journal. Key outcomes include: 100% acute pulmonary vein isolation success rate 88.27% one-year treatment success rate (PPS) No device-related serious adverse events reported Over 92.8% of procedures completed under conscious sedation, with excellent intraoperative tolerance. These results confirm NxPFA ™ 's strong performance in efficacy, safety, efficiency, and patient comfort. It remains the only PFA system globally to achieve one-shot PVI under conscious sedation with high success, marking the debut of the third-generation nanosecond PFA era. "NxPFA ™ 's approval is not only a major milestone for Pulsecare Medical but also a transformative breakthrough for cardiac electrophysiology. With NxPFA ™, we address critical clinical challenges and look forward to collaborating with global EP experts to shape the future of arrhythmia treatment—delivering smarter tools to physicians and safer, more effective, more comfortable therapies to patients," said Dr. Javen Tan, CEO of Pulsecare Medical. Founded in July 2021 and headquartered in Shenzhen, Pulsecare Medical is dedicated to the innovation and development of cardiovascular multimodal therapeutic devices. Backed by a rare cross-disciplinary team combining clinical and engineering expertise, the company is building a next-generation energy platform for interventional therapies. Pulsecare offers total solutions for cardiac electrophysiology and hypertension interventional therapy, aiming to lead in minimally and non-invasive treatments.
Toronto Star
4 hours ago
- Toronto Star
Infoblox Unveils 2025 DNS Threat Landscape Report, Revealing Surge in AI-driven Threats and Malicious Adtech
Of the 100.8 million newly observed domains, 25.1 percent were classified as malicious or suspicious 82 percent of environments contacted malicious adtech domains SANTA CLARA, Calif., Aug. 04, 2025 (GLOBE NEWSWIRE) — Infoblox, a leader in cloud networking and security services, today released its 2025 DNS Threat Landscape Report, revealing a dramatic surge in DNS-based cyberthreats and the growing sophistication of adversaries leveraging AI-enabled deepfakes, malicious adtech and evasive domain tactics.
